Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ORKA
stocks logo

ORKA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 48.25 USD with a low forecast of 40.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 48.25 USD with a low forecast of 40.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.930
sliders
Low
40.00
Averages
48.25
High
63.00
Current: 30.930
sliders
Low
40.00
Averages
48.25
High
63.00
BTIG
Julian Harrison
Buy
maintain
$56 -> $63
2025-11-13
Reason
BTIG
Julian Harrison
Price Target
$56 -> $63
2025-11-13
maintain
Buy
Reason
BTIG analyst Julian Harrison raised the firm's price target on Oruka Therapeutics to $63 from $56 and keeps a Buy rating on the shares after its Q3 results. The firm remains focused on the upcoming ORKA-002 Phase 1 HV PK data expected around 2025-end, noting that the data should confirm ORKA-002 with best-in-class half-life that could support commercially relevant improvements vs. Bimzelx, the analyst tells investors in a research note.
Jefferies
Roger Song
Buy
initiated
$45
2025-11-13
Reason
Jefferies
Roger Song
Price Target
$45
2025-11-13
initiated
Buy
Reason
Jefferies analyst Roger Song initiated coverage of Oruka Therapeutics with a Buy rating and $45 price target. The firm sees meaningful upside potential in the shares from the Phase 2a ORKA-001 study in plaque psoriasis with a readout in the second half of 2026.
H.C. Wainwright
Mitchell Kapoor
Buy
downgrade
$45 -> $40
2025-10-27
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$45 -> $40
2025-10-27
downgrade
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor lowered the firm's price target on Oruka Therapeutics to $40 from $45 and keeps a Buy rating on the shares. The firm cites the company's recent equity financing for the target drop.
Guggenheim
NULL -> Buy
initiated
$60
2025-10-27
Reason
Guggenheim
Price Target
$60
2025-10-27
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Oruka Therapeutics with a Buy rating and $60 price target, citing a positive view of its two highly optimized, best-in-class, longer-acting antibodies with validated targets. Although current biologics are highly efficacious with minimal safety risks, the firm believes Oruka's drugs could deliver rapid, deep and sustained responses with an ideal maintenance profile across multiple chronic immunology and inflammation indications, the analyst tells investors.
Clear Street
Kaveri Pohlman
Buy
initiated
$46
2025-08-20
Reason
Clear Street
Kaveri Pohlman
Price Target
$46
2025-08-20
initiated
Buy
Reason
Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics with a Buy rating and $46 price target. The firm views the stock's valuation as "compelling" following the 67% drop year-over-year. Oruka's "superior assets" are positioned to win market share in psoriasis, the analyst tells investors in a research note.
BTIG
NULL
to
Buy
initiated
$44
2025-05-22
Reason
BTIG
Price Target
$44
2025-05-22
initiated
NULL
to
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Oruka Therapeutics Inc (ORKA.O) is -11.62, compared to its 5-year average forward P/E of -6.53. For a more detailed relative valuation and DCF analysis to assess Oruka Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.53
Current PE
-11.62
Overvalued PE
-4.27
Undervalued PE
-8.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ORKA News & Events

Events Timeline

(ET)
2025-11-12
17:01:53
Oruka Therapeutics announces Q3 earnings per share of 55 cents, surpassing consensus estimate of 52 cents.
select
2025-09-29 (ET)
2025-09-29
12:46:25
Oruka Therapeutics Soars 28% Following Disappointing MoonLake Data
select
2025-09-17 (ET)
2025-09-17
05:58:12
Clear Street reports that Oruka Therapeutics data aligns with 'bull case' expectations.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-13Benzinga
Gilead Sciences Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Thursday

  • Analyst Coverage Initiations: BMO Capital initiated coverage on Veeva Systems with a Market Perform rating and a price target of $300, while Scotiabank rated Gilead Sciences as Sector Outperform with a target of $140.

  • Buy Ratings Issued: Roth Capital initiated coverage on CPS Technologies with a Buy rating and a price target of $6, and Jefferies rated Oruka Therapeutics with a Buy and a target of $45.

  • CoreWeave Rating: Compass Point initiated coverage on CoreWeave with a Buy rating and a price target of $150, reflecting positive sentiment towards the stock.

  • Current Stock Prices: As of Wednesday, Veeva closed at $296.96, Gilead at $123.40, CPS Technologies at $3.30, Oruka Therapeutics at $28.30, and CoreWeave at $85.43.

[object Object]
Preview
6.0
11-13Benzinga
AutoZone Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Thursday

  • Analyst Upgrades: Goldman Sachs upgraded AutoZone Inc. from Neutral to Buy, raising its price target from $4,090 to $4,262, while also increasing On Holding AG's target from $50 to $52, maintaining a Neutral rating.

  • Analyst Downgrades: Deutsche Bank cut Circle Internet Group Inc.'s price target from $147 to $90, maintaining a Hold rating, and Goldman Sachs downgraded Dollar Tree Inc. from Buy to Sell, lowering its target from $133 to $103.

  • Price Target Adjustments: Morgan Stanley raised Cisco Systems Inc.'s price target from $77 to $82, while B of A Securities increased FedEx Corp.'s target from $270 to $285, both maintaining their respective ratings.

  • Mixed Ratings: BTIG cut Flutter Entertainment PLC's price target from $321 to $271 but maintained a Buy rating, while HC Wainwright & Co. reduced Largo Inc.'s target from $3.7 to $2.9, also keeping a Buy rating.

[object Object]
Preview
4.0
11-13Benzinga
BTIG Reaffirms Buy Rating for Oruka Therapeutics and Increases Price Target to $63

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

  • Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

  • Market Intelligence: Users can access the most accurate stock market intelligence to improve their trading outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oruka Therapeutics Inc (ORKA) stock price today?

The current price of ORKA is 30.93 USD — it has increased 4.49 % in the last trading day.

arrow icon

What is Oruka Therapeutics Inc (ORKA)'s business?

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

arrow icon

What is the price predicton of ORKA Stock?

Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 48.25 USD with a low forecast of 40.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oruka Therapeutics Inc (ORKA)'s revenue for the last quarter?

Oruka Therapeutics Inc revenue for the last quarter amounts to -34.11M USD, increased 15.81 % YoY.

arrow icon

What is Oruka Therapeutics Inc (ORKA)'s earnings per share (EPS) for the last quarter?

Oruka Therapeutics Inc. EPS for the last quarter amounts to -21701000.00 USD, decreased -38.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oruka Therapeutics Inc (ORKA)'s fundamentals?

The market is revising No Change the revenue expectations for Oruka Therapeutics, Inc. (ORKA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 89.17%.
arrow icon

How many employees does Oruka Therapeutics Inc (ORKA). have?

Oruka Therapeutics Inc (ORKA) has 28 emplpoyees as of December 05 2025.

arrow icon

What is Oruka Therapeutics Inc (ORKA) market cap?

Today ORKA has the market capitalization of 1.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free